1.
Mult Scler Relat Disord
; 4(5): 400-402, 2015 Sep.
Artículo
en Inglés
| MEDLINE
| ID: mdl-26346786
RESUMEN
We describe a case of tumefactive multiple sclerosis, based on characteristic imaging features and excluding alternative diagnoses, presented with relapse 18 weeks after switching betaferon to fingolimod. Recent reported cases of this paradoxical demyelinating reaction in a setting of fingolimod-related immune system alterations seem to be something more than an accidental event. Immune cell shifting underlying a genetic susceptibility factor has been suggested to participate in this disastrous adverse effect. It could be a warning sign which physicians should take it into account for better recognition of patients at risk and select candidates for this management.
Asunto(s)
Clorhidrato de Fingolimod/efectos adversos , Inmunosupresores/efectos adversos , Interferón beta/efectos adversos , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/patología , Adulto , Diagnóstico Diferencial , Clorhidrato de Fingolimod/uso terapéutico , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Imagen por Resonancia Magnética , Masculino , Esclerosis Múltiple/fisiopatología , Espectroscopía de Protones por Resonancia Magnética , Tomografía
2.
Mult Scler
; 19(9): 1238-9, 2013 Aug.
Artículo
en Inglés
| MEDLINE
| ID: mdl-23339135